Family Medicine Doctors in West Sayville, NY Accepting Medicare
4 Family Medicine doctors found. Showing 1 - 4
 Adhara Haque, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 213 Montauk Hwy, West Sayville, NY 11796 Phone: 631-563-6205 Fax: 631-563-7718 |
Jasmin James, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 213 Main St Ste 2, West Sayville, NY 11796 Phone: 631-563-6205 |
 Dr. Stephen M Burke, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 213 Montauk Hwy, West Sayville, NY 11796 Phone: 631-563-6205 Fax: 631-563-7718 |
Dr. Raymond L Ebarb, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 213 Montauk Hwy, West Sayville, NY 11796 Phone: 631-563-6205 Fax: 631-563-7718 |
News Archive
Embodying racism: Race, rhinoplasty, and self-esteem in Venezuela
​Many black or racially mixed women in Venezuela are undergoing nose jobs in an effort to look whiter, but the procedure only temporarily improves their self-esteem and body image in a culture that values whiteness, a Dartmouth College study finds.
Aradigm Corporation closes transaction with Novo Nordisk A/S
Aradigm Corporation today announced that it closed the transaction contemplated by the previously announced July 30, 2010 Stock Purchase Agreement with Novo Nordisk A/S. At the closing, the Company issued 26 million shares of the Company's common stock to Novo Nordisk A/S in a private placement as consideration for the termination of a promissory note in favor of Novo Nordisk A/S under which approximately $9.1 million was outstanding on July 30, 2010, representing an effective price per share of $0.3505.
Positive results from Boston Scientific's Lotus Aortic Valve System trial
Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.
MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients
The Melanoma Research Foundation Breakthrough Consortium has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.
› Verified 1 days ago